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Description of a spontaneous expulsion of a submucosal myoma in a patient
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Introduction
Ulipristal acetate is a selective progesterone receptor mod-
ulator (SPRM). It has clinical applications in emergency
contraception and presurgical treatment of uterine myo-
mas [1].
Uterine myomas are the most common pelvic tumors
in women [2] and are frequently responsible for pre-
menopausal menometrorrhagia and pelvic pain. The most
common treatment options include surgical interventions
such as hysterectomy or myomectomy. A study on hyster-
ectomy patients found myomas in 77% of hysterectomy
specimens [3]. Several drugs have been shown to be bene-
ficial in preparation for myomectomy or vaginal hysterec-
tomy. The effects sought are a reduction in the size of
myomas and an improvement in the patient’s general
health by stopping the menorrhagia.
Clinical studies are currently underway which aim
to examine the benefits of ulipristal acetate (UPA) treat-
ment on myomas, assessing improvement of symptoms,
bleeding profile, and quality of life. It is in the context of
the PEARL III study (PGL4001’s Efficacy Assessment in
Reduction of Symptoms due to uterine Leiomyomata III)
[4] that we report a case of spontaneous expulsion of a
uterine myoma in a patient treated with UPA.
Case History
This report concerns a gravida 2 para 2 patient aged 45
with no relevant medical–surgical history who had been
suffering from menometrorrhagia for 6 months. She had
been using estrogen–progestin contraception (ethinyl-
estradiol 0.02 mg, desogestrel 0.15 mg; Deso20!) for
6 months. Menorrhagia treatment with tranexamic acid
(Exacyl!) had proven ineffective. A transvaginal ultra-
sound exam diagnosed a polyfibromatous uterus (>four
myomas with diameters of between 43 and 15 mm).
Participation in the PEARL III study (a phase III, ran-
domized, double-blind clinical study) was suggested. This
study involves the administration of UPA at a dose of
10 mg per day for 3 months. The patient is then allo-
cated, by randomization, either a progestin (norethister-
one acetate [NETA] 10 mg) or a placebo for a period of
10 days. This cycle is administered once in total and then
followed by an optional extension study, which repeats
the UPA/NETA or UPA/placebo course three more times.
Each treatment cycle is separated by an “off-drug inter-
val” allowing for return of menstruation and a full men-
strual cycle. The aim of this study was to demonstrate the
efficacy and safety of using UPA as a long-term intermit-
tent treatment of uterine myomas.
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Outcome and Follow-up
After study enrolment, the patient was given the study
medication between September 2010 and September 2011.
Amenorrhea was achieved after 3 days and persisted while
UPA was being taken, apart from intervals when the med-
ication was suspended. No adverse effects were noted and
clinical monitoring, as well as routine laboratory tests,
was normal. The sizes of the three largest myomas and
the thickness of the endometrium were measured regu-
larly via ultrasound (Fig. 1). A continuous decrease in
size of the myomas was observed over the study period.
The expulsed myoma was not one of those followed by
ultrasound measurements; however, we can assume a sim-
ilar size reduction.
Endometrial biopsies, repeated several times within the
context of the study, showed no abnormalities when
examined histologically.
At the follow-up visit of September 2011, the endova-
ginal ultrasound indicated that a myoma was in the pro-
cess of being expelled at the cervix uteri (Fig. 2). A
gynecological exam confirmed the presence of the myoma
in the endocervix. The diagnosis of spontaneous expul-
sion of submucosal myoma was postulated. Pedicle tor-
sion enabled the myoma to be extracted in the outpatient
clinic, with no complications or excessive bleeding during
the procedure.
Anatomopathological analysis confirmed the diagnosis
of a submucosal myoma of 25 9 20 9 18 mm. The
endometrium was at that time in a state of progesterone
impregnation and had a secretory appearance.
Discussion
There is a vast amount of literature published on the
treatment of uterine myomas. The growth of myomas
is not only estrogen dependent but is also influenced
by progesterone [5]. Several SPRMs have shown an
antagonist effect on myoma growth (reduction in
size) with no deleterious effect on the endometrium
[6–8].
Three recent publications have demonstrated the effect
of UPA, derived from 19-norprogesterone, on the control
of menorrhagia related to uterine myomatosis and on the
reduction in size of myomas [4, 9, 10]. UPA is an SPRM,
which acts as a progesterone receptor antagonist and can
also act as an agonist [5, 11–13] in certain conditions. It
acts specifically on the progesterone receptor with no
clinically relevant antiglucocorticoid activity (less than
mifepristone, a 19-nortestosterone derivative [14]).
Myoma expulsions reported in the published literature
are mainly expulsions secondary to postembolization
necrosis. In addition, some descriptions of myoma expul-
sion following treatment with GnRH agonists have been
published [15–17]. This is the first incidence of myoma
expulsion under SPRM treatment to our knowledge. The
link between the administration of UPA and expulsion
of the myoma in our case is not clear. In in vitro models
of myoma cell cultures, UPA has antiproliferative,
(A) (B)
Figure 1. Transvaginal ultrasound, sagittal view of the uterus: two subserosal myomas in the posterior wall. (A) before UPA treatment, (B) after
UPA-treatment. UPA, ulipristal acetate.
Figure 2. Transvaginal ultrasound, sagittal view of the cervix: 21 mm
myoma in the external orifice of the cervix. The vascular end-foot
ascends to the cervical canal. The arrow shows the internal opening
of the cervix.
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proapoptotic and antifibrotic effects [18]. Therefore, we
theorize that a reduction in the size of the myoma causes
the submucosal myoma to separate from the myometrium
and the adjacent endometrium. Then, the ischemic submu-
cosal myoma is expelled by contractions of the myometri-
um, as in a pregnancy that terminates in the first trimester.
In order to understand the molecular mechanism
responsible for the reported persistence, for several months
after treatment, of the beneficial effect of UPA on myoma
size [10], further studies are required. Optimal manage-
ment of uterine myomatosis remains a real challenge in
gynecology. It is important to be alert to the frequency of
this disease and to the presentation of its classic clinical
symptoms. Despite the abundance of published literature
on this disease, there are still numerous pathways to be
explored, particularly with regard to drug treatment. To
date, no molecule has resulted in a permanent therapeutic
solution. UPA may offer an interesting and reassuring alter-
native and longer term studies with UPA are ongoing.
Conclusion
This case describes the potential of UPA to result in size
reduction of a myoma, which can result in the expulsion
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